Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa
The inflammatory and hemostatic cardiovascular risk markers during acute hyperglycemic crisis in type 1 and type 2 diabetes
2019
Download 🢃
Authors
Popović, DraganaLalić, Katarina
Jotić, Aleksandra
Miličić, Tanja
Bogdanović, Jelena
Đorđević, Maja
Stanković, Sanja
Jeremić, Veljko
Lalić, Nebojša M.
Article (Published version)
Metadata
Show full item recordAbstract
Uvod: Analizirali smo kardiovaskularne inflamatorne (Creaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS). Metode: U tom kontekstu uključili smo grupu A: N = 20 gojaznih, B: N = 20 negojaznih bolesnika sa DKA; C: N = 10 gojaznih, D: N = 10 negojaznih bolesnika sa HHS; E: N = 15 gojaznih, F: N = 15 negojaznih kontrola. Nivo CRP IL-6 i homocistein određeni su ELISA metodom. Rezultati: Naši rezultati su pokazali niže nivoe CRP IL-6 i homocisteina nakon rešavanja AHK u poređenju sa prijemom u svim grupama: (A: p LT 0,001; B: p LT 0,001, C: p LT 0,05; D: p LT 0,001 mg/L), (A: p LT 0,001 B: p LT 0,001; C: p LT 0,05, D: p=0,001 mmol/L), (A: p LT 0,001, B: p LT 0 ,001 , C: p LT 0,001, D: p LT 0,01 pg/mL) nakon rešavanja AHK. Međutim, nivo CRP je ostao viši (p LT ... 0,001, p LT 0,01), IL-6 niži (p LT 0,05, p LT 0,001), dok je nivo homocisteina sličan u poređenju sa kontrolama. Zaključak: AHK su povezane sa povišenim nivoom inflamatornih i hemostatičnih kardiovaskularnih markera rizika. Takođe, terapija insulinom u AHK ima značajno povoljniji efekat na nivo IL-6 i homocisteina, nego na nivo CRP
Background: We analyzed cardiovascular inflammatory (Creactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). Methods: In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = 10 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N = 15 lean controls. CRP IL-6, homocysteine were determined by ELISA. Results: Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p LT 0.001; B: p LT 0.001, C: p LT 0.05; D: p LT 0.001 mg/L), (A: p LT 0.001 B: p LT 0.001, C: p LT 0.001, D: p LT 0.01 pg/mL), (A: p LT 0.001, B: p LT 0.001; C: p LT 0.05, D: p=0.001 pmol/L), respectively, at resolving AHC. However, CRP persisted higher (p LT 0.001, p LT 0.01), IL-6 lower (p LT 0.05, p LT 0.001), while homocysteine levels turned ou...t to be similar to controls. Conclusions: AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP.
Keywords:
inflamatorni markeri / hemotatski markeri / akutna hiperglikemijska kriza / inflammatory markers / haemostatic markers / cardiovascular risk markers / acute hyperglycemic crisisSource:
Journal of Medical Biochemistry, 2019, 38, 2, 126-133Publisher:
- Društvo medicinskih biohemičara Srbije, Beograd i Versita
DOI: 10.2478/jomb-2018-0024
ISSN: 1452-8258
WoS: 000460757200003
Scopus: 2-s2.0-85050080150
Collections
Institution/Community
Fakultet organizacionih naukaTY - JOUR AU - Popović, Dragana AU - Lalić, Katarina AU - Jotić, Aleksandra AU - Miličić, Tanja AU - Bogdanović, Jelena AU - Đorđević, Maja AU - Stanković, Sanja AU - Jeremić, Veljko AU - Lalić, Nebojša M. PY - 2019 UR - https://rfos.fon.bg.ac.rs/handle/123456789/1896 AB - Uvod: Analizirali smo kardiovaskularne inflamatorne (Creaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS). Metode: U tom kontekstu uključili smo grupu A: N = 20 gojaznih, B: N = 20 negojaznih bolesnika sa DKA; C: N = 10 gojaznih, D: N = 10 negojaznih bolesnika sa HHS; E: N = 15 gojaznih, F: N = 15 negojaznih kontrola. Nivo CRP IL-6 i homocistein određeni su ELISA metodom. Rezultati: Naši rezultati su pokazali niže nivoe CRP IL-6 i homocisteina nakon rešavanja AHK u poređenju sa prijemom u svim grupama: (A: p LT 0,001; B: p LT 0,001, C: p LT 0,05; D: p LT 0,001 mg/L), (A: p LT 0,001 B: p LT 0,001; C: p LT 0,05, D: p=0,001 mmol/L), (A: p LT 0,001, B: p LT 0 ,001 , C: p LT 0,001, D: p LT 0,01 pg/mL) nakon rešavanja AHK. Međutim, nivo CRP je ostao viši (p LT 0,001, p LT 0,01), IL-6 niži (p LT 0,05, p LT 0,001), dok je nivo homocisteina sličan u poređenju sa kontrolama. Zaključak: AHK su povezane sa povišenim nivoom inflamatornih i hemostatičnih kardiovaskularnih markera rizika. Takođe, terapija insulinom u AHK ima značajno povoljniji efekat na nivo IL-6 i homocisteina, nego na nivo CRP AB - Background: We analyzed cardiovascular inflammatory (Creactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). Methods: In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = 10 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N = 15 lean controls. CRP IL-6, homocysteine were determined by ELISA. Results: Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p LT 0.001; B: p LT 0.001, C: p LT 0.05; D: p LT 0.001 mg/L), (A: p LT 0.001 B: p LT 0.001, C: p LT 0.001, D: p LT 0.01 pg/mL), (A: p LT 0.001, B: p LT 0.001; C: p LT 0.05, D: p=0.001 pmol/L), respectively, at resolving AHC. However, CRP persisted higher (p LT 0.001, p LT 0.01), IL-6 lower (p LT 0.05, p LT 0.001), while homocysteine levels turned out to be similar to controls. Conclusions: AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP. PB - Društvo medicinskih biohemičara Srbije, Beograd i Versita T2 - Journal of Medical Biochemistry T1 - Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa T1 - The inflammatory and hemostatic cardiovascular risk markers during acute hyperglycemic crisis in type 1 and type 2 diabetes EP - 133 IS - 2 SP - 126 VL - 38 DO - 10.2478/jomb-2018-0024 UR - conv_787 ER -
@article{ author = "Popović, Dragana and Lalić, Katarina and Jotić, Aleksandra and Miličić, Tanja and Bogdanović, Jelena and Đorđević, Maja and Stanković, Sanja and Jeremić, Veljko and Lalić, Nebojša M.", year = "2019", abstract = "Uvod: Analizirali smo kardiovaskularne inflamatorne (Creaktivni protein (CRP), interleukin 6 (IL-6)) i (homocistein) hemotatske markere rizika u negojaznih i gojaznih pacijenata pri prijemu i razrešenju akutne hiperglikemijske krize (AHK), uključujući dijabetesnu ketoacidozu (DKA) i hiperosmolarno hiperglikemijsko stanje (HHS). Metode: U tom kontekstu uključili smo grupu A: N = 20 gojaznih, B: N = 20 negojaznih bolesnika sa DKA; C: N = 10 gojaznih, D: N = 10 negojaznih bolesnika sa HHS; E: N = 15 gojaznih, F: N = 15 negojaznih kontrola. Nivo CRP IL-6 i homocistein određeni su ELISA metodom. Rezultati: Naši rezultati su pokazali niže nivoe CRP IL-6 i homocisteina nakon rešavanja AHK u poređenju sa prijemom u svim grupama: (A: p LT 0,001; B: p LT 0,001, C: p LT 0,05; D: p LT 0,001 mg/L), (A: p LT 0,001 B: p LT 0,001; C: p LT 0,05, D: p=0,001 mmol/L), (A: p LT 0,001, B: p LT 0 ,001 , C: p LT 0,001, D: p LT 0,01 pg/mL) nakon rešavanja AHK. Međutim, nivo CRP je ostao viši (p LT 0,001, p LT 0,01), IL-6 niži (p LT 0,05, p LT 0,001), dok je nivo homocisteina sličan u poređenju sa kontrolama. Zaključak: AHK su povezane sa povišenim nivoom inflamatornih i hemostatičnih kardiovaskularnih markera rizika. Takođe, terapija insulinom u AHK ima značajno povoljniji efekat na nivo IL-6 i homocisteina, nego na nivo CRP, Background: We analyzed cardiovascular inflammatory (Creactive protein (CRP), interleukin 6 (IL-6)), haemostatic (homocysteine) risk markers in lean and obese patients at admission and acute hyperglicemic crisis (AHC) resolving, involving diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). Methods: In that context, we included group A: N = 20 obese, B: N=20 lean patients with DKA; C: N = 10 obese, D: N=10 lean patients with HHS; E: N = 15 obese, F: N = 15 lean controls. CRP IL-6, homocysteine were determined by ELISA. Results: Our results showed that CRP IL-6, and homocysteine levels decreased in all groups: (A: p LT 0.001; B: p LT 0.001, C: p LT 0.05; D: p LT 0.001 mg/L), (A: p LT 0.001 B: p LT 0.001, C: p LT 0.001, D: p LT 0.01 pg/mL), (A: p LT 0.001, B: p LT 0.001; C: p LT 0.05, D: p=0.001 pmol/L), respectively, at resolving AHC. However, CRP persisted higher (p LT 0.001, p LT 0.01), IL-6 lower (p LT 0.05, p LT 0.001), while homocysteine levels turned out to be similar to controls. Conclusions: AHC is associated with increased inflammatory and hemostatic cardiovascular risk markers. Also, insulin therapy in AHC has had more pronounced favorable effect on IL-6 and homocystein than on CRP.", publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita", journal = "Journal of Medical Biochemistry", title = "Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa, The inflammatory and hemostatic cardiovascular risk markers during acute hyperglycemic crisis in type 1 and type 2 diabetes", pages = "133-126", number = "2", volume = "38", doi = "10.2478/jomb-2018-0024", url = "conv_787" }
Popović, D., Lalić, K., Jotić, A., Miličić, T., Bogdanović, J., Đorđević, M., Stanković, S., Jeremić, V.,& Lalić, N. M.. (2019). Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa. in Journal of Medical Biochemistry Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(2), 126-133. https://doi.org/10.2478/jomb-2018-0024 conv_787
Popović D, Lalić K, Jotić A, Miličić T, Bogdanović J, Đorđević M, Stanković S, Jeremić V, Lalić NM. Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa. in Journal of Medical Biochemistry. 2019;38(2):126-133. doi:10.2478/jomb-2018-0024 conv_787 .
Popović, Dragana, Lalić, Katarina, Jotić, Aleksandra, Miličić, Tanja, Bogdanović, Jelena, Đorđević, Maja, Stanković, Sanja, Jeremić, Veljko, Lalić, Nebojša M., "Inflamatorni i hemostatski kardiovaskularni markeri rizika u toku akutne hiperglikemske krize u tipu 1 i tipu 2 dijabetesa" in Journal of Medical Biochemistry, 38, no. 2 (2019):126-133, https://doi.org/10.2478/jomb-2018-0024 ., conv_787 .